BOSTON - New research from Boston Medical Center shows that providing education and training to pediatric and family medicine providers about the importance of human papillomavirus (HPV) vaccines, in tandem with healthcare systems changes including starting an HPV vaccination series before the age of 11, improves the overall rate of HPV vaccinations among adolescent patients. HPV vaccinations can help reduce rates of HPV-related cancers, as well as play a role in reducing race- and income-related disparities in these diagnoses. Published in Pediatrics, the study results show improvements at each stage in the HPV vaccination series. Importantly, improvements were sustained beyond the conclusion of the intervention period, demonstrating that these types of programs could be used to help produce long term increases in HPV vaccination rates.
According to the Centers for Disease Control and Prevention, HPV affects nearly 80 percent of adults, and while some strains of the virus are low-risk, several strains can lead to cancer. HPV vaccination in early adolescence can prevent HPV infection, and is estimated to prevent up to 90 percent of cervical cancers. Cervical cancer disproportionately affects minority women, with Black women being twice as likely as white women to die from the disease. Because HPV vaccination can stop infections that could lead to cancer, universal HPV vaccination has the potential to reduce these disparities.
DOSE HPV (Development of Systems and Education for HPV) is a multilevel inter-professional provider training program aimed at improving HPV vaccination rates. The program educates providers on how best to communicate with parents and caregivers about HPV vaccinations, as well as how to use data in their practices to address barriers to access and completion rates of the vaccine series for their patients.
"The HPV vaccine has the potential to decrease the rates of six different types of cancer, but rates remain below national goals in the United States," says Rebecca Perkins, MD, MSc, an obstetrician and gynecologist at Boston Medical Center, and principal investigator of this research study. "Programs that produce sustained increases in HPV vaccination rates could help reduce rates of HPV-related cancers nationwide. As a gynecologist, I am particularly interested in the potential of HPV vaccination to reduce racial disparities in cervical cancer incidence and mortality."
In this randomized trial, information from 16,136 individuals between the ages of nine and 17 years-old from five pediatric primary care or family medicine practices was included in the research. At each intervention site, data about the pre and post-intervention HPV vaccination series initiation and completion was analyzed for patients with at least one visit to a clinical site and one HPV vaccination dose or a completed HPV vaccine series. The vaccine series initiation increased from 75 percent before the intervention to 90 percent after the intervention; the entire series completion rate increased from 60 percent before the intervention to 69 percent after the intervention. Importantly, rates continued to rise for 6-18 months after the intervention was completed. Given the routine recommendation of vaccination of 11 to 12 year-olds, this group was analyzed separately, with a vaccine initiation increase from 83 percent before the intervention up to 93 percent afterwards. Vaccine series completion rates increased from 54 percent pre-intervention to 69 percent post-intervention.
"Vaccination rates have significantly decreased due to COVID-19, and interventions to rapidly restore rates are needed to prevent epidemics of other vaccine-preventable diseases," says Perkins, also an associate professor of obstetrics and gynecology at Boston University School of Medicine. "The results of this study can help shed light on the importance of arming providers with the skills necessary to best communicate with families on the importance of getting vaccinations to help decrease the chances of other disease outbreaks in children and young adults." The key program components included educating providers on how to better communicate with families, decreasing missed opportunities for vaccination, and beginning the HPV vaccine series prior to age 11.
Funding for this study was provided by the American Cancer Society Research Scholar grant (128607-RSG-15-150-01-CPHPS).
About Boston Medical Center
Boston Medical Center is a private, not-for-profit, 514-bed, academic medical center that is the primary teaching affiliate of Boston University School of Medicine. It is the largest and busiest provider of trauma and emergency services in New England. Boston Medical Center offers specialized care for complex health problems and is a leading research institution, receiving more than $97 million in sponsored research funding in fiscal year 2018. It is the 15th largest funding recipient in the U.S. from the National Institutes of Health among independent hospitals. In 1997, BMC founded Boston Medical Center Health Plan, Inc., now one of the top ranked Medicaid MCOs in the country, as a non-profit managed care organization. Boston Medical Center and Boston University School of Medicine are partners in Boston HealthNet - 14 community health centers focused on providing exceptional health care to residents of Boston. For more information, please visit http://www.bmc.org.